These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 1873593

  • 1. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease.
    Przepiorka D, Shapiro S, Schwinghammer TL, Bloom EJ, Rosenfeld CS, Shadduck RK, Venkataramanan R.
    Bone Marrow Transplant; 1991 Jun; 7(6):461-5. PubMed ID: 1873593
    [Abstract] [Full Text] [Related]

  • 2. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M, Perrin MC, Belhabri A, Molina L, Nicolini F, Tigaud JD, Sotto JJ, Guyotat D, Fière D, Archimbaud E.
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [Abstract] [Full Text] [Related]

  • 3. High-dose cyclosporine and corticosteroids for prophylaxis of acute and chronic graft-versus-host disease.
    Schwinghammer TL, Bloom EJ, Rosenfeld CS, Wilson JW, Przepiorka D, Shadduck RK.
    Bone Marrow Transplant; 1995 Jul; 16(1):147-54. PubMed ID: 7581115
    [Abstract] [Full Text] [Related]

  • 4. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J, Ringdén O.
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [Abstract] [Full Text] [Related]

  • 5. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.
    Kalhs P, Brugger S, Schwarzinger I, Greinix HT, Keil F, Kyrle PA, Knöbl P, Schneider B, Höcker P, Linkesch W.
    Transplantation; 1995 Nov 15; 60(9):949-57. PubMed ID: 7491699
    [Abstract] [Full Text] [Related]

  • 6. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL, Stainer C, Hyde H, Miflin G, Haynes AP, Bessell EM, Russell NH.
    Bone Marrow Transplant; 1998 Sep 15; 22(6):541-5. PubMed ID: 9758340
    [Abstract] [Full Text] [Related]

  • 7. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
    Leelasiri A, Greer JP, Stein RS, Goodman S, Brandt SA, Edwards JR, Wolff SN.
    Bone Marrow Transplant; 1995 Mar 15; 15(3):401-5. PubMed ID: 7599565
    [Abstract] [Full Text] [Related]

  • 8. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease.
    Shepherd JD, Shore TB, Reece DE, Barnett MJ, Klingemann HG, Buskard NA, Phillips GL.
    Bone Marrow Transplant; 1988 Nov 15; 3(6):553-8. PubMed ID: 3063323
    [Abstract] [Full Text] [Related]

  • 9. Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy.
    Aschan J, Ringdén O, Sundberg B, Gahrton G, Ljungman P, Winiarski J.
    Bone Marrow Transplant; 1991 Feb 15; 7(2):113-9. PubMed ID: 2049554
    [Abstract] [Full Text] [Related]

  • 10. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease.
    Yau JC, LeMaistre CF, Zagars GK, Williams LA, Meneghetti CM, Luke DR, Dunphy FR, Spinolo JA, Jagannath S, Spitzer G.
    Bone Marrow Transplant; 1990 Apr 15; 5(4):269-72. PubMed ID: 2337738
    [Abstract] [Full Text] [Related]

  • 11. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease.
    Gondo H, Harada M, Taniguchi S, Akashi K, Hayashi S, Teshima T, Takamatsu Y, Eto T, Nagafuji K, Yamasaki K.
    Bone Marrow Transplant; 1993 Nov 15; 12(5):437-41. PubMed ID: 8298553
    [Abstract] [Full Text] [Related]

  • 12. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.
    Benekli M, Hahn T, Williams BT, Cooper M, Roy HN, Wallace P, Stewart C, Bambach B, McCarthy PL.
    Bone Marrow Transplant; 2006 Sep 15; 38(5):365-70. PubMed ID: 16862164
    [Abstract] [Full Text] [Related]

  • 13. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar 15; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

  • 14. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation.
    Solomon SR, Nakamura R, Read EJ, Leitman SF, Carter C, Childs R, Dunbar CE, Young NS, Barrett AJ.
    Bone Marrow Transplant; 2003 May 15; 31(9):783-8. PubMed ID: 12732885
    [Abstract] [Full Text] [Related]

  • 15. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan 15; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 16. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level.
    Oshima K, Kanda Y, Nakasone H, Arai S, Nishimoto N, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M.
    Am J Hematol; 2008 Mar 15; 83(3):226-32. PubMed ID: 17918253
    [Abstract] [Full Text] [Related]

  • 17. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
    Liesveld J, Duerst R, Rapoport A, Constine L, Abboud C, Packman C, Wedow L, Zwetsch L, McKenna B, Linder T, Silverman W, Swift S, Rowe J, DiPersio J.
    Bone Marrow Transplant; 1999 Sep 15; 24(5):511-6. PubMed ID: 10482935
    [Abstract] [Full Text] [Related]

  • 18. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
    Mengarelli A, Iori AP, Romano A, Cerretti R, Cerilli L, De Propris MS, Fenu S, Moleti ML, De Felice L, Girelli G, Arcese W.
    Haematologica; 2003 Mar 15; 88(3):315-23. PubMed ID: 12651271
    [Abstract] [Full Text] [Related]

  • 19. Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A.
    Izumi N, Furukawa T, Sato N, Okazuka K, Tsukada N, Abe T, Yano T, Kurasaki T, Masuko M, Toba K, Takahashi M, Aizawa Y.
    Bone Marrow Transplant; 2007 Nov 15; 40(9):875-80. PubMed ID: 17724440
    [Abstract] [Full Text] [Related]

  • 20. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease.
    Russell JA, Woodman RC, Poon MC, Jones AR, Ruether BA.
    Bone Marrow Transplant; 1994 Sep 15; 14(3):397-401. PubMed ID: 7994261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.